Clinical trials: Multiple Sclerosis Subjects
Healthy
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (i.e. how study drug is taken up by the body) of TBN in healthy participants.
- Trial name
- NCT04667013
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.
Relapsing Multiple Sclerosis
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral…
- Trial name
- NCT01047319
- Testing
- Laquinimod
- Where
- 144 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,047 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Systemic Sclerosis
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
- Trial name
- NCT04744207
- Testing
- GS-248
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 94 people
- Sponsor
- Gesynta Pharma AB
Multiple Sclerosis
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT00484536
- Testing
- CDP323
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 232 people
- Sponsor
- UCB Pharma
Relapsing Multiple Sclerosis
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a…
- Trial name
- ATTAIN (NCT01332019)
- Testing
- peginterferon beta-1a
- Where
- 151 sites in United States, Belgium and 24 more
- Volunteers
- 1,077 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
The primary objective of this study is to determine whether dimethyl fumarate (DMF) taken over 12 months is effective in reducing Multiple Sclerosis (MS)-related fatigue, as measured by mean changes in the Fatigue Scale for Motor…
- Trial name
- TECNERGY (NCT02090348)
- Testing
- dimethyl fumarate
- Sponsor
- Biogen
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Multiple Sclerosis
Oral Cladribine in Early Multiple Sclerosis (MS)
A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome).
- Trial name
- ORACLE MS (NCT00725985)
- Testing
- Cladribine, Rebif® new formulation (RNF)
- Where
- 158 sites in United States, Argentina and 32 more
- Volunteers
- 617 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South…
- Trial name
- CONTAIN (NCT01514370)
- Testing
- IFN beta 1a 44 mcg TIW, Curcumin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
This study will enroll about 66 participants who experienced a relapse of RRMS that steroids did not help. The doctor will put participants into a treatment group.
- Trial name
- OPTIONS (NCT03126760)
- Testing
- Acthar Gel
- Where
- 22 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mallinckrodt ARD LLC
Multiple Sclerosis
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
The primary objective is to assess the effect of treatment with glatiramer acetate (GA) compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the occurrence of the second clinical attack) during…
- Trial name
- PreCISe (NCT00666224)
- Testing
- Glatiramer Acetate (DB), Glatiramer Acetate (OL)
- Volunteers
- 481 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body.
- Trial name
- NCT07826689
- Testing
- PRO-1562 Oral Capsules
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Progentos Therapeutics
Relapsing Multiple Sclerosis
Atacicept in Multiple Sclerosis Extension Study, Phase II
This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects…
- Trial name
- ATAMS ext (NCT00853762)
- Testing
- Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg
- Where
- 47 sites in United States, Australia and 15 more
- Volunteers
- 74 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
- Trial name
- NCT00030966
- Testing
- Natalizumab
- Where
- 88 sites in United States, Austria and 5 more
- Volunteers
- 1,200 people
- Sponsor
- Biogen
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments.
- Trial name
- NCT04956744
- Testing
- IMS001
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImStem Biotechnology
Multiple Sclerosis
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering…
- Trial name
- RESOunD (NCT02117050)
- Testing
- Rebif®
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EMD Serono